CDTX - Cidara Therapeutics: Updates To Thesis Remains Undervalued
Shares of Cidara Therapeutics (CDTX) have lost over 60% of their value since my November 2017 article suggested that it could outperform soon. So far in 2019, the stock price has risen by over 25% (decent bounce along with the rest of the biotech sector).
Despite operating in an unloved subsector (antifungals/antibiotics), I felt this one was worth a revisit due to rezafungin's substantial market potential in infectious disease and hematology markets along with important data readouts in the near and medium term.
Chart
Figure 1: CDTX daily advanced chart (Source: Finviz)
Figure